다형성교모세포종 치료 시장 예측(-2030년) : 유형별, 약물군별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Glioblastoma Multiforme Treatment Market is accounted for $2.75 billion in 2023 and is expected to reach $5.96 billion by 2030 growing at a CAGR of 11.7% during the forecast period. Chemotherapy, radiation therapy, and surgery are frequently used in the treatment of glioblastoma multiforme (GBM). The goal of surgery is to remove as much of the tumor as possible without endangering vital brain areas. Due to the infiltrative nature of GBM cells, complete removal is frequently difficult. Radiation therapy is used after surgery to target any cancer cells that may still be present and to reduce the tumor. Moreover, the next step in the treatment is chemotherapy, which frequently uses temozolomide to further target and kill cancer cells.

According to the American Cancer Society, Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In 2021, about 1,898,160 new cancer cases are expected to be diagnosed and 608,570 Americans are projected to die from cancer.

Market Dynamics:

Driver:

Increased frequency of brain tumours

GBM is among the brain tumors that are becoming more commonplace globally. The aging of the population, exposure to the environment, genetic predispositions, and lifestyle choices are some of the factors that contribute to this trend. GBM incidence is predicted to increase in step with the world population's continued growth and aging. Furthermore, contributing to the reported rise in prevalence are developments in medical imaging and diagnostic methods that have made brain tumors easier to identify early.

Restraint:

Limited effectiveness of available therapies

The effectiveness of existing treatments for GBM is still restricted, even with improvements in treatment modalities. Chemotherapy, radiation therapy, and surgical resection can only delay the progression of the disease and reduce tumor size, offering only short-term relief. However, GBM cells frequently infiltrate the brain's surrounding tissue, making surgical removal difficult and increasing the likelihood of tumor recurrence. Additionally, the blood-brain barrier limits the effectiveness of targeted agents and chemotherapy by preventing them from reaching the brain through systemic therapies.

Opportunity:

Developments in the field of precision medicine

Optimizing treatment plans based on unique patient attributes is known as precision medicine, and it offers a bright future for enhancing GBM outcomes. Personalized treatment approaches have been made possible by the recent developments in genomic sequencing technologies and molecular profiling, which have demonstrated the heterogeneity of GBM tumors. Clinicians can select targeted therapies with a lower chance of off-target effects by identifying the precise genetic alterations and molecular signatures driving tumor growth. Furthermore, a thorough grasp of tumor biology and treatment vulnerabilities is made possible by the integration of multiomic data, such as transcriptomics, proteomics, metabolomics, and genomics.

Threat:

Tumour recurrence and therapeutic resistance

A major obstacle to the management of GBM is therapeutic resistance, which can result in tumor recurrence and the advancement of the disease. Chemotherapy, radiation therapy, and targeted agents are among the common treatment modalities to which GBM cells show both intrinsic and acquired resistance. Genetic alterations, the initiation of alternative signaling pathways, apoptosis avoidance, and the existence of cancer stem cells capable of self-renewal are examples of resistance mechanisms. Moreover, total surgical resection is difficult due to the highly infiltrative nature of GBM tumors, which leaves residual disease and the possibility of regrowth.

Covid-19 Impact:

The market for GBM treatments has been impacted by the COVID-19 pandemic in many ways. The pandemic's early effects on healthcare systems around the world caused delays in GBM patient diagnoses, starts of treatments, and enrolment in clinical trials; however, the long-term effects have been uneven. On the one hand, the pandemic accelerated the adoption of virtual care delivery models and remote patient monitoring by highlighting the significance of telemedicine solutions and robust healthcare infrastructure. However, financial limitations, disruptions in the supply chain, and the reallocation of resources have presented difficulties for both patients and healthcare providers, potentially preventing access to prompt and effective GBM treatment.

The Surgery segment is expected to be the largest during the forecast period

When it comes to treating glioblastoma multiforme (GBM), the surgery segment usually commands the largest market share. The goal of surgery is to remove as much of the tumor as possible while maintaining neurological function, which is a critical part of managing GBM. Surgical resection is still the main treatment option for debulking the tumor and reducing symptoms, even though GBM is infiltrative in nature. Modern methods like intraoperative imaging and fluorescence-guided surgery help neurosurgeons achieve the safest resection possible. However, because GBM cells are invasive and there is a chance of brain damage, complete surgical removal is frequently challenging.

The Temozolomide segment is expected to have the highest CAGR during the forecast period

In the market for Glioblastoma Multiforme (GBM) treatments, the temozolomide segment has the highest compound annual growth rate (CAGR). One of the mainstays of GBM chemotherapy is temozolomide, an oral alkylating agent that is often taken as part of the standard treatment plan after radiation therapy and surgical resection. Its widespread use is due to its capacity to cross the blood-brain barrier and cause DNA damage in order to cytotoxically affect rapidly dividing tumour cells. Moreover, temozolomide is used as maintenance therapy after radiation therapy in the adjuvant context (also referred to as concurrent chemoradiotherapy).

Region with largest share:

When it comes to the market for treatments for Glioblastoma Multiforme (GBM), North America usually has the largest share. Numerous elements contribute to this dominance, such as the high incidence of GBM cases, the sophisticated medical technology, the long-standing healthcare infrastructure, and the significant investments made in research and development. Furthermore, North America's concentration of major healthcare facilities, academic research centres, and market players encourages innovation and makes it easier for GBM patients to adopt cutting-edge treatment modalities. The region leads the industry in GBM treatment due in part to strong regulatory frameworks, favourable reimbursement policies, and a supportive regulatory environment.

Region with highest CAGR:

In the market for treatments for glioblastoma multiforme (GBM), the Asia-Pacific region is projected to grow at the highest CAGR. Factors like the rising prevalence of GBM, rising healthcare costs, increased access to cutting-edge medical facilities, and rising R&D spending in nations like China, India, Japan, and South Korea are driving this growth. Additionally, the growth of the market in the region is also influenced by initiatives to strengthen treatment facilities, advance early detection, and increase public and professional knowledge of GBM.

Key players in the market

Some of the key players in Glioblastoma Multiforme Treatment market include F. Hoffmann-La Roche Ltd., Agenus Inc., Merck & Co., Inc., Tocagen Inc., AbbVie Inc., Merrimack Pharmaceuticals Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Orbus Therapeutics Inc., Novartis AG, Activartis GmbH, DelMar Pharmaceuticals, Inc., BTG International Ltd, GT Medical Technologies, Inc. and Celldex Therapeutics Inc.

Key Developments:

In January 2024, Merck, a leading science and technology company, has announced a licensing agreement with US-based firm Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

In December 2023, Agenus Inc., a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Types Covered:

• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• Other Types

Drug Classes Covered:

• Temozolomide
• Lomustine
• Bevacizumab
• Carmustine Wafers
• Other Drug Classes

Applications Covered:

• Newly Diagnosed Glioblastoma
• Recurrent Glioblastoma
• Palliative Care
• Clinical Trials
• Pediatric Glioblastoma
• Other Applications

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Glioblastoma Multiforme Treatment Market, By Type

• 5.1 Introduction
• 5.2 Surgery
• 5.3 Radiation Therapy
• 5.4 Chemotherapy
• 5.5 Immunotherapy
• 5.6 Targeted Therapy
• 5.7 Tumor Treating Field (TTF) Therapy
• 5.8 Other Types

6 Global Glioblastoma Multiforme Treatment Market, By Drug Class

• 6.1 Introduction
• 6.2 Temozolomide
• 6.3 Lomustine
• 6.4 Bevacizumab
• 6.5 Carmustine Wafers
• 6.6 Other Drug Classes

7 Global Glioblastoma Multiforme Treatment Market, By Application

• 7.1 Introduction
• 7.2 Newly Diagnosed Glioblastoma
• 7.3 Recurrent Glioblastoma
• 7.4 Palliative Care
• 7.5 Clinical Trials
• 7.6 Pediatric Glioblastoma
• 7.7 Other Applications

8 Global Glioblastoma Multiforme Treatment Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Ambulatory Surgical Centers
• 8.4 Clinics
• 8.5 Other End Users

9 Global Glioblastoma Multiforme Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 F. Hoffmann-La Roche Ltd.
• 11.2 Agenus Inc.
• 11.3 Merck & Co., Inc.
• 11.4 Tocagen Inc.
• 11.5 AbbVie Inc.
• 11.6 Merrimack Pharmaceuticals Inc.
• 11.7 Eli Lilly and Company
• 11.8 Bristol-Myers Squibb Company
• 11.9 Pfizer Inc.
• 11.10 Orbus Therapeutics Inc.
• 11.11 Novartis AG
• 11.12 Activartis GmbH
• 11.13 DelMar Pharmaceuticals, Inc.
• 11.14 BTG International Ltd
• 11.15 GT Medical Technologies, Inc.
• 11.16 Celldex Therapeutics Inc.